We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+35.9%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.87B
AUM Growth
+$747M
Cap. Flow
+$514M
Cap. Flow %
7.48%
Top 10 Hldgs %
39.61%
Holding
82
New
19
Increased
22
Reduced
15
Closed
15

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$249M
2
MANE
Veradermics Inc
MANE
+$141M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$118M
4
COAG
Hemab Therapeutics
COAG
+$99.4M
5
UTHR icon
United Therapeutics
UTHR
+$69.6M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$182M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$125M
3
AXSM icon
Axsome Therapeutics
AXSM
+$86.7M
4
IMVT icon
Immunovant
IMVT
+$66.6M
5
BBIO icon
BridgeBio Pharma
BBIO
+$62.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
2 Miscellaneous 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MAZE
26
Maze Therapeutics
MAZE
$1.35B
$111M 1.62%
3,732,569
+255,007
+7% +$6.68M
CLDX icon
27
Celldex Therapeutics
CLDX
$3.01B
$109M 1.59%
2,939,151
+1,655,172
+129% +$53.5M
LBRX
28
LB Pharmaceuticals
LBRX
$1.39B
$109M 1.58%
3,352,804
– –
MBX
29
MBX Biosciences
MBX
$2.95B
$95.6M 1.39%
1,732,569
-1,025,000
-37% -$35.8M
GHRS icon
30
GH Research
GHRS
$1.92B
$89.6M 1.3%
+3,333,334
New +$69.6M
GMAB icon
31
CALL
Genmab
GMAB
$21.2B
$82.4M 1.2%
+3,000,000
New +$79.7M
COGT icon
32
Cogent Biosciences
COGT
$5.72B
$77.4M 1.13%
2,000,000
+1,000,000
+100% +$35M
ATAI
33
DELISTED
AtaiBeckley Inc
ATAI
$76M 1.11%
14,417,442
+2,417,442
+20% +$10.2M
UTHR icon
34
United Therapeutics
UTHR
$21.6B
$67M 0.97%
+123,616
New +$69.6M
AVTX icon
35
Avalo Therapeutics
AVTX
$878M
$66.7M 0.97%
+3,610,000
New +$57.1M
VRDN icon
36
Viridian Therapeutics
VRDN
$2.48B
$66M 0.96%
3,592,740
+2,198,796
+158% +$35.4M
CYTK icon
37
Cytokinetics
CYTK
$9.74B
$59.6M 0.87%
700,000
-674,320
-49% -$48.4M
ALT icon
38
Altimmune
ALT
$632M
$58.5M 0.85%
+19,250,000
New +$57.5M
PSNL icon
39
Personalis
PSNL
$1.73B
$53.6M 0.78%
4,000,000
+1,000,000
+33% +$8.14M
ACRS icon
40
Aclaris Therapeutics
ACRS
$773M
$49.4M 0.72%
9,345,000
– –
CRMD icon
41
CorMedix
CRMD
$610M
$49.3M 0.72%
6,274,076
– –
WGS icon
42
GeneDx Holdings
WGS
$2.92B
$48.1M 0.7%
+700,000
New +$39.8M
HROW icon
43
Harrow
HROW
$1.28B
$41.2M 0.6%
+969,000
New +$36M
CRVS icon
44
Corvus Pharmaceuticals
CRVS
$1.06B
$37.2M 0.54%
2,491,939
+400
+0% +$5.55K
SLDB icon
45
Solid Biosciences
SLDB
$905M
$35.6M 0.52%
3,565,062
– –
BEAM icon
46
Beam Therapeutics
BEAM
$2.39B
$34.3M 0.5%
1,000,000
+179,235
+22% +$5.41M
DYN icon
47
Dyne Therapeutics
DYN
$3.34B
$33.3M 0.48%
1,500,000
-500,000
-25% -$9.3M
IMMX icon
48
Immix Biopharma
IMMX
$887M
$28.6M 0.42%
+2,775,000
New +$25.7M
XFOR icon
49
X4 Pharmaceuticals
XFOR
$347M
$27.5M 0.4%
5,878,757
-460,778
-7% -$1.89M
STTK icon
50
Shattuck Labs
STTK
$606M
$25.7M 0.37%
+3,706,734
New +$23.1M
1
2
3 4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Deep Track Capital held 82 positions worth $6.87B, up 12% from $6.12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Deep Track Capital deployed $514M of net new capital in Q2 2026, opening 19 new positions and adding to 22 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 825,000 shares worth $248M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 79% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $86.7M trimmed.

  • Deep Track Capital's largest Q2 2026 buy was Alnylam Pharmaceuticals: 825,000 shares worth $248M.
  • Deep Track Capital added most to Veradermics Inc in Q2 2026, an estimated $141M increase.
  • Deep Track Capital's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $86.7M.
  • Deep Track Capital fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $182M.
  • Deep Track Capital's ten largest holdings make up 40% of its $6.87B portfolio in Q2 2026.
  • Deep Track Capital opened 19 new positions and closed 15 in Q2 2026.
  • Deep Track Capital's portfolio value rose 12% quarter-over-quarter to $6.87B.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.